Helen Dakin joined the Health Economics Research Centre in February 2008. Before starting at HERC, she worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She previously graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials.
Her current projects include: the STAR trial, which evaluates radiotherapy alongside bevacizumab (Avastin) in age-related macular degeneration; the ACHE study, which evaluates clinical tools and thresholds for selecting patients for joint replacement; and the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component.
Research paper on factors influencing NICE decisions available here.
Cooled radiofrequency ablation of the genicular nerves for chronic pain due to osteoarthritis of the knee: a cost-effectiveness analysis based on trial data.
Desai M. et al, (2019), BMC Musculoskelet Disord, 20
The Arthroplasty Candidacy Help Engine tool to select candidates for hip and knee replacement surgery: development and economic modelling.
Price A. et al, (2019), Health technology assessment (Winchester, England), 23, 1 - 216
Is stratification testing for treatment of chronic obstructive pulmonary disease exacerbations cost-effective in primary care? An early cost-utility analysis.
ABEL L. et al, (2019), International Journal of Technology Assessment in Health Care
Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL
Reed SD. et al, (2018), DIABETOLOGIA, 61, S426 - S426
Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
Becker F. et al, (2018), DIABETOLOGIA, 61, S366 - S366